Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /var/www/tarius.com/public_html/wp-content/plugins/revslider/includes/operations.class.php on line 2734

Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /var/www/tarius.com/public_html/wp-content/plugins/revslider/includes/operations.class.php on line 2738

Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /var/www/tarius.com/public_html/wp-content/plugins/revslider/includes/output.class.php on line 3679
Oncologic Drugs Advisory Committee – TARIUS – GLOBAL REGULATORY REQUIREMENTS
Loading Events

« All Events

  • This event has passed.

Oncologic Drugs Advisory Committee

February 26

During the morning session, the committee will discuss new drug application 212578 for padeliporfin di-potassium powder for solution for injection, submitted by STEBA Biotech, S.A. The proposed indication (use) for this product is for the treatment of patients with localized prostate cancer, meeting the following criteria: Stage T1-T2a and prostate specific antigen less than or equal to 10 ng/mL and Gleason Grade Group 1 based on transrectal ultrasound guided biopsy or unilateral Gleason Grade Group 2 based on multiparametric magnetic resonance imaging-targeted biopsy with less than 50 percent of cores positive.

During the afternoon session, the committee will discuss supplemental biologics license application 125477/S-034, for CYRAMZA (ramucirumab) injection for intravenous use, submitted by Eli Lilly and Company. The proposed indication (use) for this product is in combination with erlotinib, for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

Details

Date:
February 26
Event Category: